ArticleThe British journal of radiology2018
MR targeted imaging for the expression of tenascin-C in cervical cancer.
Article in The British journal of radiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 12 citations in OpenAlex.
- Breaking Through the Barrier: Nanoparticle-Driven MRI Strategies for Diagnosis and Therapy of Pancreatic Cancer.ACS nanoscience Au · 2026Review
- Advances and Challenges in the Application of Radiolabeled Magnetic Nanoparticles for Cancer Theranostics.Nuclear medicine and molecular imaging · 2025Review
- Advances in molecular imaging and targeted therapeutics for lymph node metastasis in cancer: a comprehensive review.Journal of nanobiotechnology · 2024Review
- Functional roles of magnetic nanoparticles for the identification of metastatic lymph nodes in cancer patients.Journal of nanobiotechnology · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objective: To detect cervical cancer and compare tumor invasiveness using a molecular targeted probe.
methods: Tenascin-C expression was evaluated in 15 specimens. Five of them were cervical cancer with node metastasis (group A), five were cervical cancer without node metastasis (group B), and another five were normal cervix tissues (group C). Superparamagnetic iron oxide (SPIO) nanoparticles and tenascin-C antibody were conjugated as an MR probe. After the fresh tissues incubated with the probe for 24 h, MR was performed to analysis the tissue signal changes.
results: Cervical cancer tissues with node metastasis showed highest tenascin-C expression, while normal cervix showed little expression. For the non-metastatic cervical cancer patients, tenascin-C showed moderate expression. Tenascin-C was found diffusely in the stromal surrounding malignant tumor cells. After MR, the image signal changes (contrast-to-noise ratio) kept consistent with tenascin-C expression and showed statistical difference between the three groups (A: 3.87 ± 1.45 vs B: 2.33 ± 1.04 vs C: 0.66 ± 0.31; p = 0.002).
conclusion: Tenascin-C expression can help to detect cervical cancer. MRI with SPIO-antitenascin-C may be used to evaluate the preoperative cervical cancer patients with node metastasis. ADVANCES IN KNOWLEDGE:: Tenascin-C expression can help to detect cervical cancer and compare cancer invasiveness. Protein expression difference can be captured and compared on MR with SPIO-antitenascin-C.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.